quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:35:00·52d
PRRelease
Hepion Pharmaceuticals Inc. logo

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

HEPA· Hepion Pharmaceuticals Inc.
Health Care
Original source

Companies

  • HEPA
    Hepion Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Feb 28UpdateCantor Fitzgerald$3.50

Related

  • SEC1d
    SEC Form D filed by Hepion Pharmaceuticals Inc.
  • SEC1d
    Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
  • SEC9d
    Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
  • INSIDER36d
    SEC Form 3 filed by new insider Stetz Gary S.
  • INSIDER36d
    SEC Form 3 filed by Hepion Pharmaceuticals Inc.
  • INSIDER36d
    SEC Form 3 filed by Hepion Pharmaceuticals Inc.
  • SEC36d
    Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
  • SEC43d
    SEC Form 10-K filed by Hepion Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022